This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Ophthalmology  • Ophthalmological Disorders  • Macular Degeneration  • Alert me on articles by topic  Social Bookmarking   What's this?

Commentary by Neil M. Bressler, MD

JAMA. 2004;291(15):1900-1901.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

ARCHIVES OF OPHTHALMOLOGY

Prevalence of Age-Related Macular Degeneration in the United States

The Eye Diseases Prevalence Research Group

Objective  To estimate the prevalence and distribution of age-related macular degeneration (AMD) in the United States by age, race/ethnicity, and gender.

Methods  Summary prevalence estimates of drusen 125 µm or larger, neovascular AMD, and geographic atrophy were prepared separately for black and white persons in 5-year age intervals starting at 40 years. The estimated rates were based on a meta-analysis of recent population-based studies in the United States, Australia, and Europe. These rates were applied to 2000 US Census data and to projected US population figures for 2020 to estimate the number of the US population with drusen and AMD.

Results  The overall prevalence of neovascular AMD and/or geographic atrophy in the US population 40 years and older is estimated to be 1.47% . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Progression of Age-Related Macular Degeneration After Cataract Surgery
Dong et al.
Arch Ophthalmol 2009;127:1412-1419.
ABSTRACT | FULL TEXT  

Activated VEGF Receptor Shed Into the Vitreous in Eyes With Wet AMD: A New Class of Biomarkers in the Vitreous With Potential for Predicting the Treatment Timing and Monitoring Response
Davuluri et al.
Arch Ophthalmol 2009;127:613-621.
ABSTRACT | FULL TEXT  

The rationale and evidence base for a protective role of macular pigment in age-related maculopathy
Loane et al.
Br J Ophthalmol 2008;92:1163-1168.
ABSTRACT | FULL TEXT  

Dietary {omega}-3 Fatty Acid and Fish Intake in the Primary Prevention of Age-Related Macular Degeneration: A Systematic Review and Meta-analysis
Chong et al.
Arch Ophthalmol 2008;126:826-833.
ABSTRACT | FULL TEXT  

Inhibition of Choroidal Neovascularization with an Anti-Inflammatory Carotenoid Astaxanthin
Izumi-Nagai et al.
IOVS 2008;49:1679-1685.
ABSTRACT | FULL TEXT  

Macular Pigment Lutein Is Antiinflammatory in Preventing Choroidal Neovascularization
Izumi-Nagai et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:2555-2562.
ABSTRACT | FULL TEXT  

Improved Vision-Related Function After Ranibizumab Treatment of Neovascular Age-Related Macular Degeneration: Results of a Randomized Clinical Trial
Chang et al.
Arch Ophthalmol 2007;125:1460-1469.
ABSTRACT | FULL TEXT  

Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis
Chong et al.
BMJ 2007;335:755-755.
ABSTRACT | FULL TEXT  

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: Year 1 Results of the FOCUS Study.
Heier et al.
Arch Ophthalmol 2006;124:1532-1542.
ABSTRACT | FULL TEXT  

Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld et al.
NEJM 2006;355:1419-1431.
ABSTRACT | FULL TEXT  

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown et al.
NEJM 2006;355:1432-1444.
ABSTRACT | FULL TEXT